New York, NY 9/22/08; South San Francisco, 9/26/08—Citing market instability, Fluidigm has withdrawn its registration statement for an IPO. Fluidigm, which develops microfluidic systems for drug development (see IBO 4/30/08), had originally planned to begin trading on September 19, but postponed the offering several times. Fluidigm had planned to raise $79.5 million in an offering of 5.3 million shares on the NASDAQ stock exchange at $14–$16 per share (see IBO 4/30/08). Underwriters included Morgan Stanley and UBS. Fluidigm President and CEO Gajus Worthington stated that, “we have decided to withdraw our S-1 statement rather than keep it pending. By doing so, we free ourselves of the communication restrictions that an active registration statement imposes.”